Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience

BACKGROUND: In resource-constrained areas, generic direct-acting antivirals (DAAs) have considerably reduced the cost of hepatitis C virus (HCV) therapy while there remain significant costs related to the baseline and follow-up virologic assays. AIM: The aim was to assess the efficacy and safety of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Exp Hepatol
Glavni autori: Bwa, Aung H., Nangia, Gayatri, Win, Si T.S., Maung, Soe T., Han, Khin A.W., Htar, Su S., Wine, Lei Y., Ko, Wint W., Oo, Moe P., Hlaing, Naomi K.T., Palecki, Julia, Loza, Bao L., Win, Khin M., Reddy, Rajender
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637231/
https://ncbi.nlm.nih.gov/pubmed/31360020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2018.12.001
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items